Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were "positive."
The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.
Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.
Price: 1.31, Change: +0.04, Percent Change: +3.07
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。